Beijing Northland Biotech.Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Northland Biotechnology Co., Ltd. is a research and development high-tech enterprise mainly engaged in the development of therapeutic biological products. The company was established in June 2004 and is a key high-tech enterprise under the National Torch Program, a Beijing Science and Technology Research and Development Institute, a Beijing Naked Plasmid Gene Therapy Drug Engineering Technology Research Center, and a leading enterprise in the G20 innovation of the Beijing biopharmaceutical industry. The registered capital is 257.25020.3 million yuan. The company has a high-quality R&D and management team throughout the entire pharmaceutical R&D industry chain, accumulating rich experience in preclinical research, clinical research, production and quality management, pharmaceutical factory construction, and drug management. The company has established four key technology platforms: gene vectors, animal cell culture, prokaryotic cell culture, and biological macromolecule purification, providing guarantees for the continuous development of projects. The company has a rich and highly mature pipeline for new drug research and development. Currently, three new drug projects under development have entered the clinical research stage, including recombinant human hepatocyte growth factor naked plasmid injection, recombinant human interleukin 11, which have entered phase III clinical practice, and recombinant human thymosin β Initiate Phase II clinical research. It is expected to gradually achieve the marketing and sales of new biological drugs after 2021. The company has 13 authorized patents and has undertaken 8 national level "major new drug development" projects. While adhering to independent research and development, the company has established long-term and stable cooperative relationships with leading domestic and foreign drug research and development institutions. Through joint research and development, technology transfer, equity investment, and other means, the company timely tracks the international development direction and trends of biotechnology to ensure the company's technological leadership in drug research and development and comply with international standards for drug research and development. In 2012, the company established a modern pharmaceutical enterprise - Beijing Huienland Pharmaceutical Co., Ltd. - through a joint venture with renowned Korean pharmaceutical company Huons. The company introduced advanced BFS systems and specializes in producing high-quality ophthalmic drugs. The existing single dose and multi dose production lines have passed GMP certification, with an annual production capacity of 110 million tubes. Ophthalmic drug sales have begun, and multiple varieties are currently awaiting approval. The company has achieved the integration of research and development, production, and sales, and has the ability to generate drug revenue. Adhering to the principle of "creating value and serving health", the company is committed to developing into a leading pharmaceutical enterprise in China, making positive contributions to the progress of China's pharmaceutical industry and human health. |
| Headquarter | Beijing |
| Establish Date | 6/3/2004 |
| Listed Code | 430047.BJ |
| Listed Date | 11/24/2020 |
| Chairman | Xu Songshan. |
| CEO | Xu Songshan. |
| Website | www.northland-bio.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
